Počet záznamů: 1
Unstable major molecular response as a trigger for next generation sequencing-based BCR::ABL1 mutation testing in chronic myeloid leukemia
- 1.0013632 2025 RIV US eng J
Benešová, Adéla - De Santis, S. - Polívková, Václava - Pecherková, Pavla - Křížková, Jitka - Suchánková, Pavla - Monaldi, C. - Klamová, Hana - Srbová, Dana - Žižková, Hana - Hochhaus, A. - Soverini, S. - Machová Poláková, KateřinaG
Unstable major molecular response as a trigger for next generation sequencing-based BCR::ABL1 mutation testing in chronic myeloid leukemia.
American journal of hematology. Vol. 99, no. 4 (2024), s. 759-762. ISSN 0361-8609
Grant: Ministerstvo zdravotnictví NU21-07-00225; Ministerstvo školství, mládeže a tělovýchovy LM2023033
Institucionální podpora: RVO:00023736
Klíčová slova: CML * BCR::ABL1 mutation * testing
Cite Score: 13.600, rok: 2024; SJR: 3.076, rok: 2024; IF: 9.9, rok: 2024
DOI: 10.1002/ajh.27232
Anotace: In chronic myeloid leukemia (CML) patients treated with tyrosine kinase inhibitors (TKIs), molecular response (MR) milestones have been identified that harbor prognostic significance. Major molecular response (MMR)—defined as 3-log reduction in BCR::ABL1 transcript levels from the standardized baseline on the International Scale (IS)—was the very first of such MR milestones to be recognized: It emerged at the time of the IRIS trial as a “safe haven” protecting from loss of response and progression.
Počet záznamů: 1